Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.95) by 5.26 percent. This is a 63.64 percent decrease over losses of $(0.55) per share from the same period last year.
Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.95) by 5.26 percent. This is a 63.64 percent decrease over losses of $(0.55) per share from the same period last year.
Comments